Gain Therapeutics, Inc.
GANX
$1.72
-$0.11-6.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 19.51% | -23.81% | -20.42% | -17.81% | 28.66% |
| Total Depreciation and Amortization | 52.69% | -4.12% | 63.44% | 12.50% | -3.13% |
| Total Amortization of Deferred Charges | 0.00% | 9.09% | 8.33% | 0.00% | 18.18% |
| Total Other Non-Cash Items | -44.28% | 19.83% | -54.79% | 50.30% | -9.23% |
| Change in Net Operating Assets | -37.46% | 42.25% | 15.94% | 92.95% | -148.37% |
| Cash from Operations | 8.22% | -23.71% | -33.69% | 18.92% | 11.42% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.55% | -14.86% | -9.65% | -8.23% | -9.50% |
| Issuance of Common Stock | -44.14% | -82.23% | 609.72% | 796.04% | -75.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -44.62% | -83.13% | 615.63% | 769.64% | -75.42% |
| Foreign Exchange rate Adjustments | -154.44% | -77.53% | 120.35% | -98.25% | 1,885.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -45.67% | -226.91% | 822.21% | 143.26% | -137.68% |